Skip to content

Insulin-Euglycemia Therapy in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial

Insulin-Euglycemia Therapy in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202008534546951
Enrollment
108
Registered
2020-08-07
Start date
2020-08-04
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury, Occupational Diseases, Poisoning

Interventions

insulin euglycemia therapy
Normal saline

Sponsors

Tanta University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Symptomatic acute aluminum phosphide intoxicated patients (aged 12 years or older, male or female). Patients with systolic blood pressure (SBP) =80 mmHg or pH =7.2 or HCO3 =15 meq/L will be included.

Exclusion criteria

Exclusion criteria: • Patients with co-exposure to other poisons. • Patients received medical treatment before admission. • Patients with chronic disease such as: diabetes, hepatic, renal, cardiovascular diseases. • Pregnant and lactating women. • Patients less than 12 years. • Patients died within 2 hours after admission. • Patients presented with hypoglycemia or hypokalemia on admission.

Design outcomes

Primary

MeasureTime frame
Mortality

Secondary

MeasureTime frame
• The total dose of vasopressor needed. • Need for intubation and/or mechanical ventilation. • Duration of mechanical ventilation. • The duration of hospital stay.;• Arterial blood pressure. • Blood PH and bicarbonate levels. • Serum lactate level.

Countries

Egypt

Contacts

Public ContactMarwa Shahin

Assistant Professor of Forensic Medicine and Clinical Toxicology

dmshahin2002@gmail.com00201069768108

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026